Skip to main content
Equibles
CYTOF logo

CYTOF · Altamira Therapeutics Ltd.

Track CYTOF — free

Use CYTOF with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.07 +0.00 (+0.00%) At close · Sep 1
Rebalance outlook locked
Market Cap
$405,798
Shares
5.72M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.07 Open$0.07 Day$0.07–0.07 52W close$0.05–0.15 Avg vol 30d3K Short int17K · 0.3% float · 16.4d Short vol100% DataDec 2023–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Dec 13, 2023; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+39.2%
Trailing year
Short interest
0.3%
Latest settlement · 16.4 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −3%
below
RSI (14) 51
neutral
MACD trend Positive
52-week position 22%
mid-range
Momentum
relative strength
Strong
1-month return +42%
trailing
6-month return +13%
trailing
YTD return −23%
this year
Relative strength 0%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.30% of float · ▲ +0.8% MoM · 16.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 5-yr low, contrarian setup
Squeeze score 38
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 370%
annualized · 1-yr
Max drawdown −66%
past year
ATR 12.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
51 Neutral
MACD trend
Positive Bullish
52-week position
22% Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.30% of float · ▲ +0.8% MoM · 16.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 5-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 22% Range high $0
vs 200-day avg -13% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CYTOF
Altamira Therapeutics Ltd.
this stock
$405,798 -22.8% — — 0.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +22.8% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +10.4% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $65.63B +25.5% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +411.4% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
LRI Investments, LLC
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
17.0K
Days to cover
16.4d
Change
+128 sh
View
Short Volume
Short vol %
100%
As of
Sep 2, 2026
Short Total
View
Off-Exchange
Off-exchange %
99.8%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
CHF -8.2M
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 29, 2025
This year
0
View

Performance

Raw-price comparisons begin at the captured split on Dec 13, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
CYTOF +10.9% +42.0% +12.7% +0.0% -22.8%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY +11.5% +43.2% +0.1% +0.7% -34.5%
Key facts CIK 1601936 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)